Shots:

• The companies collaborated to develop improved tissue-selective AAV vectors to realize effective gene therapy treatments for multiple life-threatening disorders
• The focus of this agreement is to develop new and modified AAV capsids that exhibit a safe product profile with improved specificity and higher gene delivery efficiency
• The collaboration comes two years after Sirion signed a similar pact with Denali Therapeutics- with other partners including Acucela and Orchard Therapeutics

 ­ Ref: Businesswire | Image: Businesswire